GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes
15. Dezember 2021 01:04 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its...
GBT Announces Proposed Offering of $250.0 Million of Convertible Senior Notes
14. Dezember 2021 07:28 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount...
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
13. Dezember 2021 09:00 ET
|
Global Blood Therapeutics, Inc.
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies...
GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition
12. Dezember 2021 09:00 ET
|
Global Blood Therapeutics, Inc.
Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta ...
GBT Announces New Employment Inducement Grants
09. Dezember 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2021, the compensation committee of GBT’s board...
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program
02. Dezember 2021 08:00 ET
|
Global Blood Therapeutics, Inc.; The ASH Research Collaborative
WASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of...
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
24. November 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th...
GBT Announces Participation in Upcoming Investor Conferences
12. November 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel...
GBT Announces New Employment Inducement Grants
08. November 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on November 1, 2021, the compensation committee of GBT’s board...
GBT Reports Third Quarter 2021 Financial Results
04. November 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target...